ROCKWOOL A/S
ROCKWOOL A/S – transactions in connection with share buy-back programme
ROCKWOOL A/S – transactions in connection with share buy-back programme
Company announcement
for ROCKWOOL A/S
Release no. 05 – 2026
to Nasdaq Copenhagen
21 January 2026
ROCKWOOL A/S – transactions in connection with share buy-back programme
As mentioned in announcement no. 07/2025, ROCKWOOL A/S has initiated a share buy-back programme which will run from 7 February 2025 until 5 February 2026. During this period, the Company will buy own shares for up to a maximum of 150 MEUR.
The programme is implemented in accordance with EU Commission Regulation No 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation.
The following transactions have been executed during the period 14 – 20 January 2026:
| Date | Number of B shares | Average purchase price B shares (DKK) | Aggregate amount, B shares (DKK) |
| [Accumulated, last announcement] | 4,254,500 | 1,099,765,036 | |
| 14 January 2026 | 25,000 | 206.84 | 5,171,000 |
| 15 January 2026 | 23,000 | 208.13 | 4,786,990 |
| 16 January 2026 | 5,000 | 209.48 | 1,047,400 |
| 19 January 2026 | 7,000 | 204.09 | 1,428,630 |
| 20 January 2026 | 5,000 | 204.36 | 1,021,800 |
| Accumulated under the programme (B shares) | 4,319,500 | 1,113,220,856 |
With the transactions stated above, ROCKWOOL A/S owns 4,766,356 B shares corresponding to 2.25 percent of the Company’s total share capital.
An overview showing the transaction data for the period 14 – 20 January 2026 is enclosed.
Further information:
Kim Junge Andersen
Senior Vice President, CFO
ROCKWOOL A/S
+45 46 55 80 15
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Verkkokauppa.com Oyj21.1.2026 13:00:00 CET | Press release
Verkkokauppa.com Oyj strengthens its management team and appoints Juha Valtonen as Chief Commercial Officer
Genmab A/S21.1.2026 12:23:17 CET | Press release
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Comphya SA21.1.2026 12:00:00 CET | Press release
Comphya Announces Publication of CaverSTIM First-in-Man Clinical Study in BJUI and Scientific Review in Nature Urology
Rias A/S21.1.2026 11:48:16 CET | Press release
Interim Report - RIAS A/S
Rias A/S21.1.2026 11:48:16 CET | Pressemeddelelse
Periodemeddelelse - RIAS A/S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom